This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study
designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy
and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics,
immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with
pembrolizumab in subjects with select advanced solid tumors.
1. All subjects' cancer must have progressed after treatment with all available therapies
that are known to confer clinical benefit, or are intolerant to treatment, or refuse
2. All subjects must have adequate archival tumor, or give consent to a fresh tumor
3. Subjects have an ECOG performance status of 0-1.
4. Subjects in monotherapy and combination therapy cohorts must have histologically or
cytologically confirmed advanced or metastatic solid tumors, including the following:
1. Melanoma (excluding uveal melanoma)
2. Cervical carcinoma
3. Pancreatic carcinoma
4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2
5. Hepatocellular carcinoma
6. Urothelial carcinoma
7. Squamous cell carcinoma of the head and neck (HNSCC)
8. Nasopharyngeal carcinoma (NPC)
9. Renal cell carcinoma
10. Microsatellite instability-high or mismatch repair deficient tumors
11. Small cell lung carcinoma or NSCLC
12. Gastric or gastroesophageal junction adenocarcinoma
13. Prostate adenocarcinoma
14. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
15. Intrahepatic cholangiocarcinoma
16. Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab
may have an advanced solid tumor that either:
- has progressed after treatment with all available therapies that are known
to confer clinical benefit, or is intolerant or has refused standard
treatment (as for the XmAb22841 monotherapy cohorts), or
- is of a tumor type for which pembrolizumab is an approved indication and has
not previously been treated with an agent targeting PD1 or PDL1.
1. Prior treatment with an investigational anti-LAG3 therapy.
2. Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for
Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, and 4P; and
within 3 weeks for Cohorts 6M, 7M, 5P, and 6P.
3. Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the
first dose of study treatment; or radiotherapy within 2 weeks of the first dose of
study treatment; or small molecule kinase inhibitors within 6 elimination half-lives
of the first dose of study treatment.
4. Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an
agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX
40, CD137) AND were permanently discontinued from that treatment due to an IRAE.
5. Failure to recover from any IRAE from prior cancer therapy to Grade ≤ 1.
6. Failure to recover from any other toxicity (other than immune-related toxicity)
related to previous anticancer treatment to Grade ≤ 2.
7. Active known or suspected autoimmune disease (except that subjects are permitted to
enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to
an autoimmune condition that is treatable with hormone replacement therapy only;
psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed
without systemic therapy; or arthritis that is managed without systemic therapy beyond
oral acetaminophen and non-steroidal anti-inflammatory drugs).
8. Receipt of an organ allograft.
9. Treatment with antibiotics within 14 days prior to first dose of study drug.
10. Participants with known HIV.
11. Participants with known chronic hepatitis B virus (HBV) infection treated for less
than 3 months prior to study enrollment and/or with a detectable HBV viral load; or
hepatitis C virus (HCV) infection that has been treated for less than 4 weeks prior to
study enrollment and/or with a detectable HCV viral load; or active HBV/HCV